Full Circles Therapeutics Secures U.S. Patent Allowance for Targeted Genome Modification Using Circular Single-Stranded DNA

CAMBRIDGE, Mass., March 7, 2025 /PRNewswire/ — Full Circles Therapeutics, a leader in next-generation genome engineering, announces that the United States Patent and Trademark Office (USPTO) has allowed its foundational patent titled “TARGETED GENOME MODIFICATION USING CIRCULAR SINGLE-STRANDED DNA.” This patent protects Full Circles’ innovative platform, which enables precise, efficient, and non-viral genome modification using circular single-stranded DNA (cssDNA), overcoming key challenges in genome engineering.

This breakthrough provides a safer, modular, and scalable alternative to viral vectors and traditional double-stranded DNA (dsDNA) donors, improving gene integration efficiency while minimizing immunogenicity, cytotoxicity, and off-target effects. With broad applications in cell and gene therapy, regenerative medicine, and biomedical research, this platform is poised to transform the field of genetic modification.

Advancing Genome Engineering with cssDNA

The growing demand for safe and efficient genome editing technologies has highlighted the limitations of viral-based gene transfer methods, such as lentiviral and adeno-associated virus (AAV) vectors, which present risks of unpredictable genomic integration, immunogenicity, and manufacturing challenges.

Full Circles’ cssDNA-based technology, dubbed C4DNA^™ GATALYST^™ genome engineering platform, enables targeted transgene integration via homology-directed repair (HDR) without the risks of viral vectors, improving precision while reducing toxicity. This makes it ideal for next-generation, virus-free therapeutic applications.

“The allowance of this patent is a significant milestone in advancing non-viral genome editing,” said Richard Shan, co-founder and Chairman of Full Circles Therapeutics. “Our proprietary cssDNA platform offers a safer and more precise alternative for gene modification, paving the way for improved allogeneic cell therapies, CAR-NK and CAR-T therapies, and other transformative treatments.”

Open for Licensing and Collaboration

To accelerate innovation, Full Circles Therapeutics is actively seeking licensing and partnership opportunities for its cssDNA platform across the biotechnology and pharmaceutical industries.

“We believe C4DNA^™ GATALYST^™ technology has immense potential across oncology, autoimmune diseases, regenerative medicine, and beyond,” said Howard Wu, co-founder and CSO. “By offering this platform for licensing, we aim to empower other innovators to enhance their gene editing capabilities and advance safer, faster, more affordable and effective therapies.”

Contact for Licensing Inquiries

For Media & Licensing Inquiries:
Flora Zhang
Director of Communications, Full Circles Therapeutics
Phone: (410) 733-0130
Email: 391251@email4pr.com 

About Full Circles Therapeutics

Full Circles Therapeutics is a pioneering biotechnology company advancing genome engineering through innovative, non-viral gene editing technologies. Its proprietary cssDNA platform is designed to enable safer, more efficient, and scalable genetic modifications, revolutionizing next-generation cell and gene therapies.

For more information, visit www.fullcirclestx.com.

View original content:https://www.prnewswire.com/news-releases/full-circles-therapeutics-secures-us-patent-allowance-for-targeted-genome-modification-using-circular-single-stranded-dna-302395179.html

SOURCE Full Circles Therapeutics